World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
Amgen's First CEO
Keywords:
George Rathmann, is the scientist at Amgen who pushed for development of EPO, a hormone which stimulates red blood cell production, when the bio-tech venture company was struggling in the mid-1980's. After approval by the EPA in 1989, Epogen became Amgen's main product with sales of $2 billion in 2011. Rathmann graduated from Northwestern University, and received his PhD. from Princeton University in physical chemistry. He helped develop Scotchguard at 3M, and later headed the R&D department at the diagnostics division of Abbott Laboratories. He built Amgen from a staff of four in the early days in 1980, and it was his intuitive sense that Amgen should focus its entire effort on EPO development in the mid-1980's that led to its success.
Amgen legal settlements
04/10/2007
Grouped Articles
Amgen to Pay $780 Million to Settle Marketing Accusations
New York Times 10/24/2011
Wall Street Journal 04/23/2012
Amgen's Star Fades Amid Safety Questions
Wall Street Journal 04/10/2007
Amgen partnership with generics manufacturer Watson Pharmaceuticals
10/22/2006
Grouped Articles
Generic-Drug Firms Go Beyond Knockoffs
Wall Street Journal 06/15/2013
Amgen and Watson to Work Together on Generic Drugs
New York Times 12/19/2011
Wall Street Journal 04/23/2012
More Low-Cost Generics - WSJ.com
Wall Street Journal 10/22/2006
Amgen's Star Fades Amid Safety Questions
Wall Street Journal 04/10/2007
Amgen strategies
04/10/2007
Grouped Articles
Amgen Strikes $10.4 Billion Deal for Onyx
Wall Street Journal 08/26/2013
Amgen Buys Producer of Drugs for Cancer
New York Times 08/25/2013
Amgen's Star Fades Amid Safety Questions
Wall Street Journal 04/10/2007
Amgen Cuts Mark Biotech Squeeze
Wall Street Journal 08/16/2007
Amgen Selling Japanese Rights to Some Drugs
New York Times 02/05/2008
Amgen Gets a Lift in Deal With Takeda
Wall Street Journal 02/05/2008
Biotech pharmaceutical startups wither in the new economic climate- 2007-2010
04/09/2007
Biotech starups are running short of cash in large numbers and some are in bankruptcy liquidation.
Grouped Articles
Wall Street Journal 07/01/2013
BusinessWeek 04/09/2007
Cash-Poor Biotech Firms Cut Research, Seek Aid
Wall Street Journal 10/29/2008
Big Pharma's Costly Debt Addiction
Wall Street Journal 02/09/2009
Cash Dries Up for Biotech Drug Firms
Wall Street Journal 03/16/2009
High-Tech Auctions Crowd Silicon Valley
Wall Street Journal 03/16/2009
Amgen founder biotech scientist Rathmann
04/10/2007
Grouped Articles
George Rathmann, Chief of Amgen, Dies at 84
New York Times 04/23/2012
Wall Street Journal 04/23/2012
Amgen's Star Fades Amid Safety Questions
Wall Street Journal 04/10/2007
Wall Street Journal 01/13/2011
Amgen management
04/10/2007
Grouped Articles
Amgen and Watson to Work Together on Generic Drugs
New York Times 12/19/2011
Wall Street Journal 04/23/2012
Amgen's Star Fades Amid Safety Questions
Wall Street Journal 04/10/2007
Amgen performance
04/10/2007
Grouped Articles
Amgen Strikes $10.4 Billion Deal for Onyx
Wall Street Journal 08/26/2013
Amgen Buys Producer of Drugs for Cancer
New York Times 08/25/2013
Amgen and Watson to Work Together on Generic Drugs
New York Times 12/19/2011
Wall Street Journal 04/23/2012
Amgen's Star Fades Amid Safety Questions
Wall Street Journal 04/10/2007
Biotech pharmaceutical companies and industry.
03/14/2007
Grouped Articles
Wall Street Journal 07/01/2013
New Medicines Emerge, but Few Blockbusters
Wall Street Journal 12/16/2013
Potential for Deals Drives a Big Surge in the Biotech Sector
New York Times 07/11/2013
Biotech Stocks' Rout Perplexes Analysts
Wall Street Journal 04/11/2014
For Booming Biotech Firms, A New Threat: Generics
Wall Street Journal 03/14/2007
BusinessWeek 04/09/2007
U.S. biotech companies and industry
01/13/2011
Grouped Articles
Wall Street Journal 07/01/2013
Wall Street Journal 07/01/2013
Potential for Deals Drives a Big Surge in the Biotech Sector
New York Times 07/11/2013
Wall Street Journal 07/25/2015
Wall Street Journal 09/29/2015
Wall Street Journal 11/22/2011
Amgen founder Rathmann and venture startups in the biotech industry
03/16/2009
Rathmann's focus on EPO when Amgen was near bankruptcy in the mid-1980's saved the company. By 1989 Amgen had secured FDA approval for Epogen, a hormone based drug to stimulate the production of red blood cells. This is a rare success in a biotech industry with many failed startup ventures or ventures strugglig with only 6-12 months of cash remaining.
Linked Articles
Cash Dries Up for Biotech Drug Firms
Wall Street Journal 03/16/2009
Wall Street Journal 04/23/2012
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us
